Codeine, ephedrine, promethazine

Sold as Lenazine forte cough, Antituss cough, Sedlinct, Dequa-coff, Brunacod

S2Read from the PI-PIL document and verified

Combination product

This product contains more than one active ingredient, so it has no single molecular structure.

Loading Wikipedia summary

Registration

Applicants: 3
Registrations: 5
Schedule source: SAHPRA documentation

Applicants and registrations

Applicant	Brands	Dosages	Registrations	Schedule	Leaflets
Pharmacare limited û woodmeadCertificate held by Pharmacare limited	Lenazine forte cough, Dequa-coff	9 mg/7,2 mg/3,6 mg per 5 ml, syrup	G0533, G1008	S2	PI PIL
The Premier Pharmaceutical Co LtdCancelled	Antituss cough, Sedlinct	linctus, mixture	G0666, G0748	Not determined	None
Inova Pharmaceuticals (Pty) Ltd	Brunacod	Not stated	G1064	Not determined	None

Variants

Product	Strength and form	Registration	Status	Schedule	Leaflets
Lenazine forte cough linctus EACH 5 ML LINCTUS CONTAINS CODEINE PHOSPHATE A 9 MG EPHEDRINE HYDROCHLORIDE A 7,2 MG PROMETHAZINE HYDROCHLORIDE A 3,6 MG	9 mg/7,2 mg/3,6 mg per 5 mlFlavoured syrup base.	G0533Approved 11 December 2023	Old Medicine	S2	PI PIL
Antituss cough linctus 5 ML CODEINE PHOSPHATE A 9 MG EPHEDRINE HYDROCHLORIDE A 7,2 MG PROMETHAZINE HYDROCHLORIDE A 3,6 MG	Linctus	G0666	Cancelled	Not determined	None
Sedlinct mixture 5 ML CODEINE PHOSPHATE A 9 MG EPHEDRINE HYDROCHLORIDE A 7,2 MG PROMETHAZINE HYDROCHLORIDE A 3,6 MG	Mixture	G0748	Cancelled	Not determined	None
Dequa-coff syrup 5 ML CODEINE PHOSPHATE A 9,0 MG EPHEDRINE HYDROCHLORIDE A 7,2 MG PROMETHAZINE HYDROCHLORIDE A 3,6 MG	Syrup	G1008	Old Medicine	Not determined	None
Brunacod EACH 5,0 ml SYRUP CONTAINS CODEINE PHOSPHATE A 9,2 mg EPHEDRINE HYDROCHLORIDE A 7,0 mg PROMETHAZINE HYDROCHLORIDE A 3,0 mg	Not listed	G1064	Old Medicine	Not determined	None

Regulatory status

Where S2 sits on the scale

S0S1S2S3S4S5S6S7S8

A pharmacist can sell it directly, without a prescription.

Schedule 2 medicines sit behind the pharmacy counter. A pharmacist can decide to sell one of these directly, using their own professional judgement, without a doctor's prescription. It can also be dispensed against a prescription like the higher tiers, in which case the usual repeat limits apply. A child under 12 may only be sold a Schedule 2 substance on a prescription, or on a written order that names the purpose and carries a signature the seller recognises. Even though it cannot be advertised to the public in the ordinary sense, its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.

Schedule S2, read from the product's PI-PIL leaflet.

The Consolidated Schedules list this ingredient up to S6; the leaflet's S2 applies to this product.

Who may supply: Only a pharmacist, pharmacist intern or supervised pharmacist's assistant may sell it without a prescription. It may otherwise be dispensed by a pharmacist against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.

Consolidated Schedules listings for Codeine phosphate, ephedrine hydrochloride, promethazine hydrochloride

S6: Codeine
- single component codeine preparations;
- oral solid preparations, in combination with one or more therapeutically active substances, in preparations not registered in terms of the Act, or when intended for export; (S2, S3)
- liquid oral preparations and mixtures, in combination with one or more therapeutically active substances, in preparations not registered in terms of the Act, or when intended for export. (S2, S3)
Consolidated Schedules 06 July 2026, lines 10128 to 10136
S6: Ephedrine
- except products registered in terms of the Act, not intended for export, and being oral preparations and mixtures, in combination with another pharmacologically active substance and intended for the symptomatic relief of colds and flu, containing not more than 30 milligrams of ephedrine per dose, with a maximum daily dose not exceeding 120 milligrams, subject to a maximum pack size of 360 milligrams and limited to one pack per customer; (S2)
- except preparations and mixtures intended for application to the skin, eyes, ears and nares and containing 1 percent or less of ephedrine. (S1)
Consolidated Schedules 06 July 2026, lines 10226 to 10235
S3: Codeine
- oral solid preparations, in combination with one or more therapeutically active substances, containing more than 10 milligrams of codeine (calculated as base) per dosage unit, when contained in products registered in terms of the Act, and not intended for export;
- liquid oral preparations and mixtures, in combination with one or more therapeutically active substances, containing more than 10 milligrams of codeine (calculated as base) per 5 millilitre dosage unit, when contained in products registered in terms of the Act, and not intended for export;
- except oral solid preparations, in combination with one or more therapeutically active substances, containing not more than 10 milligrams of codeine (calculated as base) per dosage unit, with a maximum daily dose not exceeding 80 milligrams, and in packs containing sufficient dosage units for a maximum treatment period of 5 days and limited to one pack per customer, when contained in products registered in terms of the Act, and not intended for export; (S2)
- except liquid oral preparations and mixtures, in combination with one or more therapeutically active substances, containing not more than 10 milligrams of codeine (calculated as base) per 5 millilitre dosage unit, with a maximum daily dose not exceeding 80 milligrams, and with a pack size not exceeding 100 millilitres and limited to one pack per customer, when contained in products registered in terms of the Act, and not intended for export; (S2)
- except single component codeine preparations. (S6)
Consolidated Schedules 06 July 2026, lines 3350 to 3372
S2: Codeine
- oral solid preparations, in combination with one or more therapeutically active substances, containing not more than 10 milligrams of codeine (calculated as base) per dosage unit, with a maximum daily dose not exceeding 80 milligrams, and in packs containing sufficient dosage units for a maximum treatment period of 5 days, and limited to one pack per customer, when contained in products registered in terms of the Act, and not intended for export;
- liquid oral preparations and mixtures, in combination with one or more therapeutically active substances, containing not more than 10 milligrams of codeine (calculated as base) per 5 millilitre dosage unit, with a maximum daily dose not exceeding 80 milligrams, and with a pack size not exceeding 100 millilitres, when contained in products registered in terms of the Act, and not intended for export;
- except oral solid preparations, in combination with one or more therapeutically active substances, containing more than 10 milligrams of codeine (calculated as base) per dosage unit; (S3)
- except liquid oral preparations and mixtures, in combination with one or more therapeutically active substances, containing more than 10 milligrams of codeine (calculated as base) per 5 millilitre dosage unit; (S3)
- except single component codeine preparations. (S6)
Consolidated Schedules 06 July 2026, lines 1758 to 1778
S2: Ephedrine
- contained in products registered in terms of the Act, and not intended for export,
- oral preparations and mixtures, in combination with another pharmacologically active substance and intended for the symptomatic relief of colds and flu, containing not more than 30 milligrams of ephedrine per dose, with a maximum daily dose not exceeding 120 milligrams, subject to a maximum pack size of 360 milligrams and limited to one pack per customer; (S6)
- except preparations and mixtures intended for application to the skin, eyes, ears and nares and containing 1 percent or less of ephedrine. (S1)
Consolidated Schedules 06 July 2026, lines 1899 to 1907
S2: Promethazine
- when intended for use as an antihistamine, and
- when intended for application to the skin, and
- when intended specifically for the treatment of travel sickness. (S5)
Consolidated Schedules 06 July 2026, lines 2586 to 2592
S1: Ephedrine
- preparations and mixtures intended for application to the skin, eyes, ears and nares and containing 1 percent or less of ephedrine, and not intended for export; (S6)
- except products registered in terms of the Act, not intended for export, and being oral preparations and mixtures, in combination with another pharmacologically active substance and intended for the symptomatic relief of colds and flu, containing not more than 30 milligrams of ephedrine per dose, with a maximum daily dose not exceeding 120 milligrams, subject to a maximum pack size of 360 milligrams and limited to one pack per customer. (S2)
Consolidated Schedules 06 July 2026, lines 410 to 419

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

SAHPRA documents

Schedule verified from official documents

Schedule Verification

Lenazine forte cough linctus, Pharmacare limited û woodmead is scheduled S2 in its official SAHPRA documents, read with 90% confidence.

Professional information (PI)For healthcare professionalsLenazine forte cough linctus, Pharmacare limited û woodmead Patient information leaflet (PIL)For patients and carersLenazine forte cough linctus, Pharmacare limited û woodmead

These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.

Research articles

Loading PubMed articles

Background